Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): The OCOG ZAMBONEY study

Mark J. Clemons, Brandy Cochrane, Gregory R. Pond, Nadia Califaretti, Stephen K.L. Chia, Rebecca Alexandra Dent, Xinni Song, Andre Robidoux, Sameer Parpia, David Warr, Daniel Rayson, Kathleen I. Pritchard, Mark N. Levine

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)
Original languageEnglish
Pages (from-to)153-162
Number of pages10
JournalBreast Cancer Research and Treatment
Volume146
Issue number1
DOIs
Publication statusPublished - Jul 2014
Externally publishedYes

ASJC Scopus Subject Areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): The OCOG ZAMBONEY study'. Together they form a unique fingerprint.

Cite this